加科思-B(01167.HK)LIF單抗JAB-BX300於內地臨牀試驗申請獲批

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

加科思-B(01167.HK)LIF單抗JAB-BX300於內地臨牀試驗申請獲批

阿思達克 04-04 12:30

加科思-B(01167.HK)宣佈，自主研發的LIF(白血病抑制因數)單抗JAB-BX300於2023年4月4日收到藥監局(NMPA)藥品審評中心(CDE)臨新藥臨牀試驗批準(IND)，將在中國開展I/IIa期晚期實體瘤臨牀試驗。

加科思-B(01167.HK)

Relevant Stocks

加科思-B(01167.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

加科思-B(01167.HK)LIF單抗JAB-BX300於內地臨牀試驗申請獲批

Services

About Us

Agreement Statement